利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.034 秒)

    METHODS FOR TREATING HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERCHOLESTEROLEMIA
    6.
    发明申请
    METHODS FOR TREATING HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERCHOLESTEROLEMIA 审中-公开
    用高胆固醇血症治疗高血压风险患者的方法

    公开(公告)号：US20160137746A1

    公开(公告)日：2016-05-19

    申请号：US14801392

    申请日：2015-07-16

    申请人： Sanofi Biotechnology ,  Regeneron Pharmaceuticals, Inc.

    发明人： Corinne Hanotin ,  Laurence Bessac ,  Umesh Chaudhari ,  Robert Pordy ,  Daniel A. Schwemmer Gipe

    IPC分类号： C07K16/40

    CPC分类号： C07K16/40 ,  A61K39/39533 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76

    摘要： The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and established CHD or CHD risk equivalents that are not adequately controlled by maximum tolerated dose statin therapy.

    摘要翻译： 本发明提供治疗高胆固醇血症的方法。 本发明的方法包括向高心血管危险患者施用包含PCSK9抑制剂的药物组合物。 在某些实施方案中，PCSK9抑制剂是抗PCSK9抗体，例如本文称为mAb316P的示例性抗体。 本发明的方法可用于治疗高胆固醇血症的高心血管风险患者和建立的不被最大耐受剂量他汀类药物治疗适当控制的CHD或CHD风险等同物。

    METHODS FOR REDUCING CARDIOVASCULAR RISK
    7.
    发明申请
    METHODS FOR REDUCING CARDIOVASCULAR RISK 审中-公开

    公开(公告)号：US20190292273A1

    公开(公告)日：2019-09-26

    申请号：US16294635

    申请日：2019-03-06

    申请人： SANOFI BIOTECHNOLOGY ,  REGENERON PHARMACEUTICALS, INC.

    发明人： Corinne Hanotin ,  Laurence Bessac ,  Robert C. Pordy ,  William J. Sasiela ,  Gregory G. Schwartz ,  Philippe Gabriel Steg

    IPC分类号： C07K16/40 ,  A61P9/00

    摘要： The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.

    METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH)
    8.
    发明申请
    METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) 审中-公开
    用异种家族性高脂血症患者（heFH）治疗患者的方法

    公开(公告)号：US20160137745A1

    公开(公告)日：2016-05-19

    申请号：US14801384

    申请日：2015-07-16

    申请人： Sanofi Biotechnology ,  Regeneron Pharmaceuticals, Inc.

    发明人： Marie Baccara-Dinet ,  Corinne Hanotin ,  Laurence Bessac ,  Umesh Chaudhari ,  Robert C. Pordy ,  William J. Sasiela ,  Daniel A. Schwemmer Gipe

    IPC分类号： C07K16/40

    摘要： The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.

    摘要翻译： 本发明提供治疗高胆固醇血症的方法。 本发明的方法包括向具有杂合家族性高胆固醇血症的患者施用包含PCSK9抑制剂的药物组合物。 在某些实施方案中，PCSK9抑制剂是抗PCSK9抗体，例如本文称为mAb316P的示例性抗体。 本发明的方法可用于治疗在具有或不具有其它降脂治疗的情况下不能通过最大耐受剂量他汀类药物治疗而充分控制的杂合家族性高胆固醇血症的患者。

    METHODS FOR REDUCING CARDIOVASCULAR RISK
    10.
    发明申请
    METHODS FOR REDUCING CARDIOVASCULAR RISK 有权

    公开(公告)号：US20220144969A1

    公开(公告)日：2022-05-12

    申请号：US17504921

    申请日：2021-10-19

    申请人： SANOFI BIOTECHNOLOGY ,  REGENERON PHARMACEUTICALS, INC.

    发明人： Laurence Bessac ,  Corinne Hanotin ,  Robert C. Pordy ,  William J. Sasiela ,  Gregory G. Schwartz ,  Philippe Gabriel Steg

    IPC分类号： C07K16/40 ,  A61K31/40 ,  A61K39/395 ,  A61K31/505

    摘要： The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.